Publications by authors named "Bethlehem Shiberu"
The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for effective prophylactic vaccination to prevent the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Intranasal vaccination is an attractive strategy to prevent COVID-19 as the nasal mucosa represents the first-line barrier to SARS-CoV-2 entry. The current intramuscular vaccines elicit systemic immunity but not necessarily high-level mucosal immunity.
View Article and Find Full Text PDFArticle Synopsis
- - The COVID-19 pandemic has highlighted the need for effective vaccinations to combat the spread of SARS-CoV-2, with a focus on intranasal vaccines as they target the nasal mucosa, the first barrier to infection.
- - Current vaccines mainly provide systemic immunity via intramuscular injection, lacking the ability to activate mucosal defenses.
- - The AdCOVID vaccine, an intranasal adenovirus-based vaccine, successfully induces strong immune responses, including mucosal IgA and T cells, making it a promising candidate for COVID-19 prevention.
The genome of Helicobacter pylori 26695 has been sequenced and the lipopolysaccharide (LPS) O sidechain of this strain has been shown to express both Lewis x and Lewis y units. To determine the role of HP0159 and HP1416, genes recognized as rfaJ homologs and implicated in LPS synthesis, isogenic mutants of H. pylori 26695 were generated.
View Article and Find Full Text PDF